Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 22, 46 Issues, 2016

Download PDF Flyer

Current Pharmaceutical Design

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 62nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.452
5 - Year: 3.504

Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer

Current Pharmaceutical Design, 20(41): 6466-6471.

Author(s): Irena Draskovic and Arturo Londono-Vallejo.

Affiliation: UMR3244; Institut Curie, 26 rue d'Ulm, 75248 Paris, France.


Telomeres are essential for cell proliferation and tumor cell immortalization requires the presence of a telomere maintenance mechanism. Thus, interfering with this mechanism constitutes a potential means to impede cell proliferation and tumor progression. Many cancer cells rely on telomerase activity to ensure indefinite proliferation capacity and developing therapeutic approaches that target telomerase has attracted much attention in the last couple of decades. Nevertheless, a non-negligible proportion of tumors utilize telomerase- independent, alternative mechanisms to lengthen telomeres (ALT). Here we briefly discuss both our current understanding of ALT mechanisms and the potential to develop a therapeutic approach targeting ALT.


Telomere, recombination, ALT-associated PML body, chromatin, orphan receptors, variant repeats, histone 33.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 41
First Page: 6466
Last Page: 6471
Page Count: 6
DOI: 10.2174/1381612820666140630085857

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science